Nycomed Imaging As

Nycomed Innovation Ab

Amersham Health As

Ge Healthcare As

Picker Nordstar Oy

Hafslund Nycomed Innovation Ab

Ib Leunbach

Klaes Golman

Stefan Petersson

Jan Henrik Ardenkjaer-Larsen

Oskar Axelsson

Lars-Goran Wistrand

Georg Hansson

Jo Klaveness

Arne Berg

Pangl Rongved

Goran Pettersson

Peter Leander

Gosta J Ehnholm

Harald Dugstad

Torsten Almen

Sven Goran Andersson

Unni Nordby Wiggen

Tomas Klingstedt

Ian R Young

Wolfgang H Gunther

Rune Fossheim

Hangkan Wikstrom

Sven Månsson

O Slashedyvind Antonsen

Jan Henrik Ardenkj&aelig;r-Larson

Lars-G&ouml;ran Wistrand

The present invention provides a method of MR investigation of a sample, said method comprising: (i) nuclear spin polarizing a high T1 MR imaging agent which contains in its molecular structure at least two hyperpolarisable nuclei within the same molecule, the frequency difference between the two resonance lines from said nuclei, &#x3b4;&#x3c5;, being dependent upon either the temperature or the pH of said sample; (ii) administering the nuclear spin polarized MR imaging agent to said sample; (iii) exposing said sample to a radiation at a frequency selected to excite nuclear spin transitions in said MR imaging agent; and (iv) detecting and manipulating magnetic resonance signals from said sample using a single-shot RARE acquisition sequence with shifted data acquisition.

MR-method for the in vivo measurement of temperature or pH-value by means of a hyperpolarised contrast agent

The present invention provides a method of magnetic resonance investigation of a sample, preferably of a human or non-human animal body. The method comprises the step of ex vivo polarization of a high T agent. The polarizing agent is optionally separated from the high T agent before the high T agent is administered to the sample.

Method of magnetic resonance investigation

The invention relates to a method of magnetic imaging (MR) of a living sample comprising the steps of hyperpolarizing a hyperpolarizable gas ex-vivo and transferring the nuclear polarization from the hyperpolarized gas to the nuclei of an MR imaging agent, that is not hyperpolarizable, that is exposed to a uniform magnetic field and that is introduced in contact to the hyperpolarizable gas, separating the hyperpolarizable gas from the MR imaging agent, administering the MR imaging agent to the living sample, exciting NMR transitions in the nuclei of the imaging agent and detecting an NMR signal thereof.

Method of magnetic resonance imaging

The present invention provides a method of magnetic resonance investigation of a sample, preferably of a human or non-human animal body, said method comprising the step of ex vivo polarisation of a high T,agent and wherein the polarising agent is optionally seperated from the high T,agent before the high T,agent is administered to the sample.

Method of magnetic resonance imaging of a sample with ex vivo polarization of an MR imaging agent

A method for determining the oxygen concentration of a sample using electron spin resonance enhanced magnetic resonance imaging.

Method for determining oxygen concentration

This invention relates to a method of electron spin resonance enhanced magnetic resonance imaging which relies on ex vivo dynamic nuclear polarisation of an MR imaging agent.

Nuclear Polarization Enhanced Nuclear Magnetic Resonance Imaaging

The invention provides low viscosity iodinated aryl compounds, useful as X-ray contrast agents, of formula I ##STR1## (wherein n is 0 or 1, and where n is 1 each C.sub.6 R.sub.5 moeity may be the same or different; each group R is a hydrogen atom, an iodine atom or a hydrophilic moiety M or M.sub.1, two or three non-adjacent R groups in each C.sub.6 R.sub.5 moiety being iodine and at least one, and preferably two or three, R groups in each C.sub.6 R.sub.5 moiety being M or M.sub.1 moieties; X denotes a bond or a group providing a 1 to 7 atom chain linking two C.sub.6 R.sub.5 moieties or, where n is 0, X denotes a group R; each M independently is a non-ionic hydrophilic moiety; and each M.sub.1 independently represents a C.sub.1-4 alkyl group substituted by at least one hydroxyl group and optionally linked to the phenyl ring via a carbonyl, sulphone or sulphoxide group, at least one R group being an M.sub.1 moiety; with the proviso that where n is zero either at least one M.sub.1 group other than a hydroxymethyl or 1,2-dihydroxyethyl group is present or then if one hydroxymethyl or 1,2-dihydroxyethyl M.sub.1 group is present at least one nitrogen-attached or hydroxylated-C.sub.3-4 alkyl moiety-containing M group is also present) and isomers thereof.

Contrast media

There is provided a contrast medium composition comprising: (a) a first contrast agent comprising a physiologically tolerable manganese compound, a physiologically tolerable reducing compound containing an .alpha.-hydroxy ketone group, or salt thereof, having a manganese concentration of at least 0.3 mM or being in a dosage unit form containing at least 300 .mu.mol manganese, together with (b) a second contrast agent. Such compositions have been found to be particularly suited to imaging of the liver.

Contrast agents for MRI using a manganese compound and kojic acid

There is provided a contrast medium composition comprising: (a) a first contrast agent comprising a physiologically tolerable manganese compound together with an uptake promoter, having a manganese concentration of at least 0.3 mM or being in a dosage unit form containing at least 300 .mu.mol manganese, wherein the uptake promoter comprises a physiologically tolerable reducing compound containing an .alpha.-hydroxy ketone group or a physiologically tolerable acid containing .alpha.- and/or .beta.- hydroxy or amino groups, or a salt thereof, and/or vitamin D; together with (b) a second contrast agent. Such compositions are particularly suitable for imaging of the liver.

Composition and method of MRI using both a positive and a negative

Method for determining oxygen concentration using magnetic resonance

Stable free radical containing contrast media

The invention relates to a modification of electron spin resonance enhanced magnetic resonance imaging (ESREMRI) in which two magnetically responsive materials (contrast agents) are introduced into the sample being investigated, one contrast agent serving as an ESREMRI free induction decay signal enhancing agent and the other as enhancement suppressing agent. In this way, image contrast may be enhanced further for regions in which the suppressing agent distributes poorly or not at all or which the suppressing agent reaches at a later time than the enhancing agent.

Composition of positive and negative contrast agents for electron spin

Electron spin resonance enhanced MRI using an echo planar imaging

Thermographic imaging

Magnetic resonance imaging

Growing community of inventors

Dragor, Denmark

Ib Leunbach